Impact Biomedical (IBO) Net Income Growth (1y) (2023 - 2026)

Impact Biomedical (IBO) Net Income Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 67,132.22 Bn 67,131.94 Bn - -0.46%
2 Nanobiotix 1,910.87 Bn 1,910.81 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.60 Bn 466.80 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.71 Bn 114.46 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.83 Bn 61.07 Bn 3.31 Bn -10.08%
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.65 Bn 1.41 Bn 63.48%
9 Alnylam Pharmaceuticals 37.33 Bn 34.32 Bn 959.66 Mn 1,228.66%
10 Impact Biomedical 47.43 Mn 47.41 Mn - -78.72%

Historic Data

Download Data
DateValue
Mar 31, 2026 -78.72%
Sep 30, 2025 -134.78%
Jun 30, 2025 -1,523.53%
Mar 31, 2025 -28.06%
Dec 31, 2024 -2,049.09%
Sep 30, 2024 460.32%
Jun 30, 2024 21.14%
Mar 31, 2024 -17.55%
Dec 31, 2023 62.54%
Sep 30, 2023 47.36%
Jun 30, 2023 -40.30%